Last reviewed · How we verify
A hydrogel containing erythropoietin
Stimulates erythropoiesis by binding to and activating the erythropoietin receptor
Stimulates erythropoiesis by binding to and activating the erythropoietin receptor Used for Anemia associated with chronic kidney disease, Anemia associated with cancer chemotherapy.
At a glance
| Generic name | A hydrogel containing erythropoietin |
|---|---|
| Also known as | Standard of care (SOC) |
| Sponsor | Remedor Biomed Ltd |
| Drug class | Erythropoiesis-stimulating agent |
| Target | Erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Erythropoietin binds to its receptor on the surface of erythroid progenitor cells, triggering a signaling cascade that promotes the proliferation and differentiation of these cells into mature red blood cells.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia associated with cancer chemotherapy
Common side effects
- Thromboembolism
- Hypertension
- Headache
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A hydrogel containing erythropoietin CI brief — competitive landscape report
- A hydrogel containing erythropoietin updates RSS · CI watch RSS
- Remedor Biomed Ltd portfolio CI